Lapisteride

Lapisteride (CS 891) is an orally active 5α-reductase inhibitor. Lapisteride can inhibit 5α-reductaseactivity in the hair follicles (HF) . Lapisteride can be used in prostatic hyperplasia and androgenic alopecia research[1][2].

Product Specifications

CAS Number

[142139-60-4]

Product Name Alternative

CS 891

UNSPSC

12352005

Target

5 alpha Reductase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Endocrinology

Assay Protocol

https://www.medchemexpress.com/lapisteride.html

Purity

99.0

Solubility

Ethanol : 100 mg/mL (ultrasonic)

Smiles

C[C@@]12[C@](CC[C@@H]2C(NC(C)(C3=CC=C(C=C3)OC)C)=O)([H])[C@@]4([H])[C@@](CC1)([H])[C@@]5([C@@](NC(C=C5)=O)([H])CC4)C

Molecular Formula

C29H40N2O3

Molecular Weight

464.64

References & Citations

[1]Yada S, et al. Solid phase transition of CS-891 enantiotropes during grinding. Int J Pharm. 2003 Apr 14;255 (1-2) :69-79. |[2]Niiyama S, et al. The novel drug CS-891 inhibits 5alpha-reductase activity in freshly isolated dermal papilla of human hair follicles. Eur J Dermatol. 2000 Dec;10 (8) :593-5.